



Level 8 Cell Culture Processing (BIO08045)

Lecture 1 – "Introduction to Cell Culture Processing"

- Dermot O' Sullivan
- Dermot.osullivan@nibrt.ie



Learning Objectives

What is biotechnology in the context of biotherapeutics?

A brief history of modern biotechnology.

Examples of biopharmaceutical drug products and their origins.



Lecture Topics

What is Biotechnology?

Developing Cell Lines for Bioprocessing.


Mammalian Cell Lines for Bioprocessing.

Monoclonal Antibodies.




What is Biotechnology?

 Biotechnology is any technological application that uses biological systems, living organisms or derivatives of them, to make or modify products or processes.






Evolution of Modern Biotechnology






Evolution of Modern Biotechnology




www.alnylam.com/our-science/the-science-of-rnai

How do mRNA vaccines work?



www.infors-ht.com/en/blog/mrna-technology-how-a-platform-is-revolutionizing-the-biopharmaceutical-industry/



www.cambridge.org/core/journals/mrs-bulletin/news/crisprimplications-for-materials-science



2022 Sales

| | Product | Active Substance | Company | Indication | Sales 2022 (\$bn) |
|----|-----------|---|-----------|-------------------------------|-------------------|
| 1 | Comirnaty | Tozinameran | Pfizer | Covid Vaccine | 55.9 |
| 2 | Humira | Adalimumab | Abbvie | Arthritis, Crohn's Disease | 21.2 |
| 3 | Keytruda | Pembrolizumab | Merck | Oncology | 20.9 |
| 4 | Paxlovid | Nirmatrelvir | Pfizer | COVID-19 | 18.9 |
| 5 | Spikevax | Elasomeran | Moderna | COVID-19 Vaccine | 18.4 |
| 6 | Eliquis | Apixaban | BMS | Blood clots, stroke | 18.2 |
| 7 | Dupixent | Dupilumab | Sanofi | Allergic Disease | 17.4 |
| 8 | Eylea | Aflibercept | Regeneron | Oncology | 12.7 |
| 9 | Biktarvy | Bictegravir/emtricitabine/ tenofovir alafenamide | Gilead | HIV/AIDS | 10.3 |
| 10 | Revlimid | Lenalidomide | Celgene | Oncology | 10.0 |



Biologic

Small Molecule



2028 Predicted Sales

| | Product | Active Substance | Company | Indication | Predicted Sales 2028 (\$bn) |
|----|----------------------|---|----------------|------------------------------|--------------------------------|
| 1 | Keytruda | Pembrolizumab | Merck | Oncology | 31.1 |
| 2 | Opdivo | Nivolumab | BMS | Oncology | 14.7 |
| 3 | Dupixent | Dupilumab | Sanofi | Allergic Disease | 14.4 |
| 4 | Darzalex | Daratumumab | 181 | Oncology | 14.1 |
| 5 | Ozempic | Semaglutide | Novo Nordisk | Diabetes / Obesity | 13.8 |
| 6 | Biktarvy | Bictegravir/emtricitabine/ tenofovir alafenamide | Gilead | HIV/AIDS | 11.6 |
| 7 | Skyrizi | Risankizumab | AbbVie | Psoriasis/Crohn's Disease | 11.3 |
| 8 | Trikafta/ Kaftrio | Elexacafotr/tezacaftor/ ivacaftor | Vertex | Cystic Fibrosis | 10.3 |
| 9 | Comirnaty | Tozinameran | Pfizer | COVID-19 Vaccine | 9.7 |
| 10 | Imbruvica | Ibrutinib | J&J and AbbVie | Oncology | 9.7 |





Biologic

Small Molecule

Sligo


Development of an Industrial Bioprocess








Development of an Industrial Bioprocess





From Cryovial to Production





Cell Culture Processing

Tissue Culture Flasks



Spinner Flask



Disposable Bioreactor

Cell Stock

Vial





Shake Flasks



Bench top bioreactor



Stainless steel Production Bioreactor



Biopharmaceuticals

- Biopharmaceuticals are medicinal compounds produced using biotechnology: produced in microbial, plant and mammalian cells.
 - They involve incorporation of foreign DNA into an organism's genetic material to generate a genetically modified organism (GMO) producing elevated amounts of a therapeutic protein.

Majority of biopharmaceuticals are proteins or glycoproteins
 (i.e. proteins with sugars) so referred to as 'Therapeutic proteins'.

 Companies also use the term "Recombinant Products" as products are produced using recombinant DNA technology.



Biologics versus Small Molecule Drugs



Aspirin (180.2 Da)




Atorvastatin (558.6 Da)



(206.3 Da)

| Small Molecules | Typical Attributes | Biologics |
|-----------------|--------------------------|----------------|
| Oral | Administration route | Parenteral |
| Higher | Stability | Lower |
| Higher | Side effects | Lower |
| Systemic | Mode of action | Specific |
| Easier | Manufacturing | More Difficult |
| Lower | Immunogenicity potential | Higher |
| Lower | Half-life | Higher |




Infliximab (~150,000 Da)




So Why Biologics?

- > Small molecule drugs often lack specificity which can cause off-target interactions and side-effects.
- ➤ Biologics can be engineered to **act with extreme precision** resulting in less side effects and lower toxicity.
- ➤ Biologics can target complex molecular processes that small molecules cannot can treat diseases such as cancer or autoimmune diseases.






Why Biologics? Lock and Key Model



https://biochemchica.files.wordpress.com/2013/03/lock1.jpg



http://psych.hanover.edu/classes/neurop sychology/WebNotes/Images/lockkey.gif



https://upload.wikimedia.org/wikipedia /commons/thumb/2/2d/Antibody.svg/2 000px-Antibody.svg.png



Lecture Topics

What is Biotechnology?

Developing Cell Lines for Bioprocessing.

Mammalian Cell Lines for Bioprocessing.

Monoclonal Antibodies.




Cell Line Definition

Cell line = a culture developed from a single cell and therefore consisting of cells with a uniform genetic make-up.

Primary cell culture = derived directly from living tissue – begins with many cells ∴ more variation.

Cell lines are often immortalised and grow continuously in culture.


Immortalised cells may be cancerous, arise spontaneously or be transformed.






Importance of Genetic Engineering

- Plasmid is removed from bacterium and DNA is removed from cell nucleus.
- Restriction enzymes are used to cut plasmid open and remove desired gene from DNA.
- Biochemically bind desired gene into open plasmid.
- Genetically modified plasmid is reintroduced into bacterium.
- Recombinant DNA reproduces and producing cells are selected for growth.






Summary of Protein Synthesis Process





Proteins: Post-translational modifications


- Chemical modification of a protein after translation (ribosomal synthesis).
- Proteins can undergo >100 different types of PTM* which can influence structural aspects and/or the functional roles of the protein.
- Modulates molecular interactions, protein localisation and stability.
- Involves:
 - Covalent addition of functional groups.
 - Proteolytic cleavage of regulatory subunits.
 - Degradation of entire proteins.





Proteins: Post-translational modifications


Important PTMs for biopharmaceuticals:



Most common form of PTM on biopharmaceuticals

Seen on many biopharmaceuticals.

Only seen on a small number of biopharmaceuticals.





Choosing a Cell Type

For Simple Proteins



YEAST

- Simpler Fermentation
- Scalable
- Lower Cost of Goods
- Post-translational Modifications that are not human-like


For Complex Proteins



- Complex Culture
- Less Scalable
- High Cost of Goods
- Human-like PTMs



Prokaryotic Vs Eukaryotic



Cytoplasmic membrane
Endoplasmic reticulum
Ribosomes

Nucleus
Nucleolus
Nuclear membrane
Cytoplasm
Mitochondrion
Chloroplast (plants only)

10 µm

(b)

Prokaryotic cell e.g. E. coli

Eukaryotic cell e.g. Mammalian Cell

Protein synthesis begins in the cell's <u>nucleus</u> (or the nucleoid for prokaryotic cells)



Prokaryotic Vs Eukaryotic

Prokaryote

Small & simple

No nucleus

No membrane-bound organelles

Intracellular expression

Doubling time approx. 20mins

No complex PTMs

May have cell wall

Easier to grow and shear resistant

Eukaryote

Large & complex

Nucleus

Membrane-bound organelles

Extracellular expression


Doubling time approx. 24hours


Complex PTMs

Usually no cell wall - fragile

More difficult to grow and shear/osmotic stress sensitive

Prokaryote e.g. E. coli





Eukaryote e.g. CHO



Examples of Industrial Cell Lines

Human

-HEK293 (Human Embryonic Kidney)

- Per C.6

Hamster

-CHO (Chinese Hamster Ovary)

- BHK (Baby Hamster Kidney)

Mouse

-NSO (Non-secreting Myeloma)

- SP2/0 (Non-secreting Hybridoma

Monkey

- Vero (Green Monkey)

Yeast

- S. cerevisae

- P. pastoris

Bacteria

- E. coli

Insect

- Sf 9/21 (Fall Army Worm)

Plant

-Carrot



Bacteria As Host Cells

ADVANTAGES

Simple system, easily manipulated.

Short generation times (i.e. grow quickly).

Large yields at low cost.

Some can secrete protein into the culture medium (e.g. Bacillus subtilis).

DISADVANTAGES

High level of expression but may not fold properly.


Protein not secreted can form insoluble bodies.

Cannot modify protein i.e. glycosylation (addition of sugar groups) so protein may be biologically inactive.






Spiral






Yeast As Host Cells

- Yeast cells are single cell eukaryotes which are a type of fungi.
- They are small in size, ~2μm and have a cell wall, membrane and organelles.
- Used in brewing, baking and biopharmaceutical production.





ADVANTAGES

Well developed genetic tools.

Simple eukaryote & resemble mammalian cells.

Grow as quickly & cheaply as bacteria.

DISADVANTAGES

Protein yields can be low.

Foreign proteins can be toxic to yeast.

Can get hyperglycosylation (multiple sugars added).



Plant Cells As Host Cells

ADVANTAGES

Production of pharmaceuticals (e.g. taxol), biodegradable plastics.

Production of vaccines : food based vaccines.

Alter nutritional content of plants, e.g. decrease fat content, increase vitamin.

Introduction of herbicide and pest resistance genes.

DISADVANTAGES

Procedure for getting DNA into plants cells very complex.

Plants cell in culture difficult to maintain and grow.

Not possible to do large-scale culture of plant cells.

PLANT CELL





Lecture Topics

What is Biotechnology? Developing Cell Lines for Bioprocessing. Mammalian Cell Lines for Bioprocessing. Monoclonal Antibodies.



Why Mammalian Cells?

| | Mammalian Cells | Bacteria/Yeast |
|-----------------------------------|-----------------|----------------|
| Correct protein folding | \checkmark | |
| Protein secretion | | |
| PTMs | | × |
| Large, complex protein production | | × |
| Good regulatory track record | | |
| Fast growth and cheap media | × | |
| Simple purification protocols | × | \checkmark |
| Animal component free media | × | |
| Simple to characterize | × | |



Criteria for Cell Line Selection

Before manufacture ever begins, some questions need to be asked;

Product type?

- Simple recombinant protein
- Monoclonal antibody
- Fusion protein

Genetic Stability?

- Stability of transfection
- Long-term genetic stability

Growth and productivity in large scale culture?

- Ease of selection of high producers
- Adaptation to protein-free suspension culture
- Apoptosis, proliferation rate, max cell number

Safety issues?

- Potential for endogenous viral contamination
- Use of animal products in media (potential contamination)



Common Examples of Industrial Cell Lines

| Abbreviation | Full Name | Origin | History | Companies |
|--------------|---------------------------------|-------------------------------|-----------------------------------|---|
| СНО | Chinese Hamster Ovary | Fibroblast from hamster ovary | Used for mutation research in 50s | Genentech, BMS, Lilly, Janssen, Pfizer |
| NS0 | Mouse non- secreting myeloma | Mouse lymphocyte | Mouse lymphocyte | Alexion, Biogen |
| Per.C6 | Human | Human retinal cell | Fully human PTMs | Crucell, DSM, Merck |



How are Cell Productivity Improvements Achieved?

Generation of recombinant cell lines with high specific productivities



Formulation of media to support high density cell cultivation



Understanding of bioprocess conditions for cell cultivation



Sustained viability of cell lines in highdensity batch and fed-batch cultures

| Parameter | 1986 | Today |
|---------------------|------|-------|
| Protein Pg/cell/day | 10 | 90 |


| Parameter | 1986 | Today |
|--------------|----------------------------|------------------------------|
| Cell Density | 2x10 ⁶ cells/mL | >20x10 ⁶ cells/mL |

| Parameter | 1986 | Today |
|------------------|--------|---------|
| Process duration | 7 days | 21 days |

| Parameter | 1986 | Today |
|-----------|---------|--------|
| Titres | 50 mg/L | >5 g/L |



Lecture Topics






Monoclonal antibodies (MAb)

- The first monoclonal antibody in Ireland was made at Wyeth (Pfizer) Biopharma facility in 2004; this antibody was anti Tumour Necrosis Factor (anti-TNF)
- TNF is a protein released by immune system if it senses damage to cells in body
- In diseases, sometimes the body is fooled into believing cells are being damaged and continually releases TNF (problems caused by excess TNF production are rheumatoid arthritis, Crohn's disease, Alzheimer's disease and diabetes)
- Antibody (anti TNF) binds TNF and stops pain and swelling
- Examples of Mab's:
 - Herceptin produced in CHO cells for breast cancer treatment
 - <u>Remicade</u> produced in myeloma cells to treat Crohn's and arthritis
 - Enbrel produced in CHO cells to treat rheumatoid arthritis




Origin of Monoclonal Antibodies






Antibodies: Structure

- Antibodies or immunoglobulins: 2 polypeptide chains (heavy and light chains) held together by disulfide bonds
- Each chain contains a constant and variable region
- End of each chain is specific for a particular antigen: determined by sequence of variable region: antigen binding site (ABS)
- Sequence of ABS is referred to as complementary determining regions (CDRs) changes with to different antibodies







The Evolution of Antibodies As Drugs





The Evolution of Antibodies As Drugs





Fusion Proteins-combination of two different proteins to result in antibody with properties of both. E.g. Enbrel, Eylea, Zaltrap



Summary

- Biotechnology for the biopharma industry is about production of biologically active molecules, predominantly proteins, for use as therapeutics or vaccines.
 - Can be produced in bacteria, yeast, plant or animal cells.
 - For human use, mammalian cell lines are preferred as they post-translationally modify proteins similar to human proteins.
- Relies on the use of genetically engineered cell lines designed to produce large amounts of the target protein.
- MAbs represent one of the major types of protein produced as a biotherapeutic.
- Originated in mouse systems and now humanised for improved compatibility with the human recipient.



Questions?





Sample Questions

- Glycosylation is a critical post-translational modification for many biotherapeutic proteins - explain why?
- Originally, monoclonal antibodies were produced in mice. Why are these no longer used and what steps have been taken to overcome their limitations?
- For biomanufacturing purposes, what types of cells may be used as "cell factories"? Discuss their relative pros and cons.
- Which cell types are generally preferred for production of products for use in humans and why?